Mundipharma A/S: Financial statements 2024
CVR: 17981994
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Mundipharma A/S (CVR 17981994) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 26,430,000 and a net result of DKK 514,000 compared with DKK 897,000 the year before. That is a decrease of 26.5% compared with the year before. The profit margin was 1.9%. Equity in the 2024 report amounted to DKK 37,493,000. The solvency ratio was 69.5%. The company had 2 employees in the financial year.
- Revenue
- DKK 26,430,000
- Gross Profit
- DKK 3,057,000
- Profit/Loss
- DKK 514,000
- Equity
- DKK 37,493,000
- Total Assets
- DKK 53,921,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 26.4M | 3.1M | 514K | 37.5M | 2 |
| 2023 | 35.9M | 3.1M | 897K | 37M | 2 |
| 2022 | 40.1M | 6.8M | 709K | 49.8M | 4 |
| 2021 | 48.5M | 10.5M | 910K | 49.1M | 9 |
| 2020 | 51.6M | 30.8M | 908K | 48.2M | 21 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of July 26, 2024, Lisbeth Kattenhøj has joined the board of directors of Mundipharma A/S.
As of July 26, 2024, Hywel Rhys Day has left the board of directors of Mundipharma A/S.
As of July 26, 2024, Floris Anne Everard Bongenaar has left the board of directors of Mundipharma A/S.
As of July 26, 2024, Lisbeth Kattenhøj is registered as director of Mundipharma A/S.
As of July 26, 2024, Hywel Rhys Day has stepped down as adm. dir. of Mundipharma A/S.
Mundipharma A/S has published its annual report for 2023. Revenue came to DKK 35,938,000, and the net result was DKK 897,000.
About Mundipharma A/S
Mundipharma A/S is a Danish company of the type Aktieselskab based in Vedbæk, founded in 1994. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Norpharma A/S and NORPHARMA A/S. The management consists of Lisbeth Kattenhøj. The board consists of Stephen Johan Jamieson (chair), Bryan George Lea and Lisbeth Kattenhøj. The company is owned by Halm S.à.r.l., RSS Captain Trust Holdings LLC and JDS Captain Trust Holdings LLC. The company has 3 employees (2026). In 2025, the company reported revenue of DKK 25,912,000 and a net result of DKK 672,000 compared with DKK 514,000 the year before. Equity in the 2025 report amounted to DKK 38,165,000.
